InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech

Deal Overview:
InnoCare Pharma and KeyMed Biosciences have sold the international rights (excluding China) to a clinical-stage bispecific antibody to a new biotech company created by RTW Investments in a deal worth up to $520 million134.

Payment Structure:
The deal includes initial and short-term payments, with total payments reaching as much as $520 million4.

Partnership:
This partnership highlights the strategic collaboration between Chinese biotechs and international investors, aiming to advance the development and global distribution of innovative biotechnological products.

Clinical Stage:
The bispecific antibody is in the clinical stage, indicating that it has shown promising results in early trials and is moving forward in the development process.

RTW Investments:
RTW Investments is a venture capital firm that has created a new biotech company to acquire and develop the bispecific antibody, demonstrating its commitment to investing in innovative biotechnology projects2.

Sources:

1. https://www.finanznachrichten.de/nachrichten-medien/fiercebiotech.htm

2. https://www.fiercebiotech.com/venture-capital

3. https://biotechjobs.io/2025/01/21/innocare-keymed-sell-ex-china-rights-for-bispecific-to-rtw-built-biotech-in-520m-deal/

4. https://www.indiapharmaoutlook.com/news/innocare-and-keymed-bags-licensing-deal-for-bispecific-antibody-icpb02-nwid-3013.html